baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Genmab A/S/ DK0010272202 /

6/20/2025 5:00:45 PM	Chg. -33.00	Volume	Bid5:00:45 PM	Ask5:00:45 PM	Market Capitalization	Dividend Y.	P/E Ratio
1,373.00DKK	-2.35%	53,843 Turnover: 35.42 mill.	-Bid Size: -	-Ask Size: -	91.14 bill.DKK	-	11.27

GlobeNewswire 6/12 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

GlobeNewswire 6/2 BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commerc...

GlobeNewswire 5/27 BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting

GlobeNewswire 5/13 Immatics Announces First Quarter 2025 Financial Results and Business Update

GlobeNewswire 5/12 Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire 5/8 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 5/5 BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

GlobeNewswire 5/5 BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

GlobeNewswire 5/2 Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administrat...

GlobeNewswire 4/24 BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Pr...

GlobeNewswire 4/22 BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

GlobeNewswire 4/15 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

GlobeNewswire 4/8 Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development

GlobeNewswire 3/24 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Busine...

GlobeNewswire 3/22 Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

GlobeNewswire 3/10 Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GlobeNewswire 3/10 BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

GlobeNewswire 2/24 BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March...

GlobeNewswire 2/12 Genmab Publishes 2024 Annual Report

GlobeNewswire 2/3 BioNTech Completes Acquisition of Biotheus

GlobeNewswire 8/30/2024 HOOKIPA Pharma Announces Board of Directors Changes

GlobeNewswire 8/22/2024 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...

GlobeNewswire 8/19/2024 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...

GlobeNewswire 8/16/2024 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

GlobeNewswire 8/13/2024 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Genmab A/S/ DK0010272202 /

If you wish to receive reply to your feedback, please provide your email address.